143 related articles for article (PubMed ID: 18930278)
1. Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer.
Tsuchiya N; Inoue T; Narita S; Kumazawa T; Saito M; Obara T; Tsuruta H; Horikawa Y; Yuasa T; Satoh S; Habuchi T
J Urol; 2008 Dec; 180(6):2389-95. PubMed ID: 18930278
[TBL] [Abstract][Full Text] [Related]
2. Association analysis of glutathione-S-transferase P1 (GSTP1) polymorphism with urothelial cancer susceptibility and myelosuppression after M-VAC chemotherapy.
Yokomizo A; Yamamoto K; Kinukawa N; Tsunoda T; Koga H; Naito S
Int J Urol; 2007 Jun; 14(6):500-4. PubMed ID: 17593093
[TBL] [Abstract][Full Text] [Related]
3. [Clinical evaluation of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy for advanced urothelial cancer].
Mikami K; Nakagawa S; Takada H; Ebisui K; Sugimoto K; Watanabe H; Maegawa M; Nakao M
Hinyokika Kiyo; 1994 Apr; 40(4):303-7. PubMed ID: 8191968
[TBL] [Abstract][Full Text] [Related]
4. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
[TBL] [Abstract][Full Text] [Related]
5. Possible survival benefit of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin combination therapy (HD-MVAC) over conventional MVAC in metastatic urothelial carcinoma patients.
Inoue T; Obara T; Saito M; Kumazawa T; Yuasa T; Matuura S; Tsuchiya N; Satoh S; Habuchi T
Hinyokika Kiyo; 2007 Sep; 53(9):613-8. PubMed ID: 17933135
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of M-VAC chemotherapy combined with mild hyperthermia, a new therapeutic strategy for advanced or metastatic transitional cell carcinoma of the urothelium.
Yamada Y; Itoh Y; Aoki S; Nakamura K; Taki T; Naruse K; Tobiume M; Zennami K; Katsuda R; Kato Y; Watanabe M; Nishikawa G; Minami M; Nakahira M; Ukai S; Sawada M; Kitamura A; Honda N
Cancer Chemother Pharmacol; 2009 Nov; 64(6):1079-83. PubMed ID: 19277660
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study of modified M-VAC therapy with one 21-day cycle for advanced urothelial cancer].
Nakanishi S; Matsuzaki M; Morikawa H; Nakano M; Komatsu H
Hinyokika Kiyo; 2004 Oct; 50(10):667-71. PubMed ID: 15575216
[TBL] [Abstract][Full Text] [Related]
8. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
[TBL] [Abstract][Full Text] [Related]
9. Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.
Long HJ; Monk BJ; Huang HQ; Grendys EC; McMeekin DS; Sorosky J; Miller DS; Eaton LA; Fiorica JV;
Gynecol Oncol; 2006 Mar; 100(3):537-43. PubMed ID: 16216315
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of side effects caused by intra-arterial and intravenous infusion of M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) for urothelial cancer].
Uchida J; Okada H; Ohguchi N; Kawa G; Koyama Y; Mikami O; Kawamura H; Ohhara T; Matsuda T
Hinyokika Kiyo; 1997 Sep; 43(9):637-40. PubMed ID: 9365842
[TBL] [Abstract][Full Text] [Related]
11. Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer.
Siefker-Radtke AO; Millikan RE; Tu SM; Moore DF; Smith TL; Williams D; Logothetis CJ
J Clin Oncol; 2002 Mar; 20(5):1361-7. PubMed ID: 11870180
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
Soga N; Arima K; Sugimura Y
Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
[TBL] [Abstract][Full Text] [Related]
13. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
Raj GV; Iasonos A; Herr H; Donat SM
J Clin Oncol; 2006 Jul; 24(19):3095-100. PubMed ID: 16809735
[TBL] [Abstract][Full Text] [Related]
14. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
[TBL] [Abstract][Full Text] [Related]
15. Association between patient characteristics and treatment history, and toxicity associated with methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) for advanced urothelial cancer.
Igawa M; Kadena H; Ueda M; Usui T
Br J Urol; 1994 Mar; 73(3):263-7. PubMed ID: 8162503
[TBL] [Abstract][Full Text] [Related]
16. The evolving role of chemotherapy in advanced urothelial cancer.
Calabrò F; Sternberg CN
Curr Opin Support Palliat Care; 2007 Oct; 1(3):180-6. PubMed ID: 18685360
[TBL] [Abstract][Full Text] [Related]
17. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
Fukuda H; Mitsumori K; Minagawa S; Kumazawa T; Tadachi K; Iinuma M; Satoh S; Satoh K; Habuchi T; Kato T
Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365
[TBL] [Abstract][Full Text] [Related]
18. Current optimal chemotherapy for advanced urothelial cancer.
Sonpavde G; Galsky MD; Hutson TE
Expert Rev Anticancer Ther; 2008 Jan; 8(1):51-61. PubMed ID: 18095883
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of cisplatin and methotrexate after M-VAC chemotherapy for advanced urothelial cancer in hemodialysis patients.
Matsumoto K
Int J Urol; 2008 Oct; 15(10):949-50. PubMed ID: 19138292
[No Abstract] [Full Text] [Related]
20. Factors that Predict Neutropenia in Korean Patients with Advanced Urothelial Cancer after Cisplatin- Based Systemic Chemotherapy.
Kwon WA; Oh TH; Lee JW; Seo IY; Park SC
Urol J; 2018 Jul; 15(4):168-172. PubMed ID: 29681054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
